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Introduction
Kaposi’s Sarcoma (KS) is an angiogenic multifocal proliferative 
tumor which can arise in the skin, mucosa surfaces, and internal organs 
[1]. Elderly men of the Eastern- Mediterranean origin, Blacks living in 
the Sub-Saharan region, immunosupressed patients, and homosexual 
or bisexual men infected with the human immunodeficiency virus type 
1, are at high risk of developing different clinical and epidemiological 
forms of KS (classical KS, African KS, post-transplant KS, and AIDS-
KS respectively) [1]. Infections with the Kaposi’s Sarcoma Associated 
Herpes Virus (KSHV or HHV-8) play a key role in the development 
and pathogenesis of KS by inducing the proliferation of cells and 
release of angiogenic growth factors [2,3]. Histologically, KS lesions are 
characterized by proliferating spindle cells, angiogenesis, erythrocyte-
replete vascular slits, profuse edema, and a variable inflammatory 
cell infiltrate [1]. KS spindle cells and infiltrating inflammatory cells 
elaborate a variety of pro-inflammatory and angiogenic factors which 
are thought to induce the progression of KS by autocrine and paracrine 
mechanisms [4]. 
Among the many cytokines accumulated in KS lesions, Fibroblast 
Growth Factor 2 (FGF-2 or basic FGF), plays an important role in the 
pathogenesis of KS [5,6]. FGF-2 is a potent angiogenic growth factor 
which lacks a classic signal peptide for secretion and is released from 
cells by non-conventional pathways [7-9]. FGF-2 also synergizes with 
the HIV-1 protein Tat to promote angiogenesis and tumor growth 
in AIDS-KS lesions [5] and Tat has been shown to be able to induce 
angiogenesis. Interestingly, the release of biologically active FGF-
2 is controlled by neighboring as well as invading inflammatory 
cells. A major control mechanism of FGF-2 local paracrine activity 
is extracellular sequestration followed by its selective release [8,9]. 
Heparan sulfate proteoglycans (HSPG) in the extracellular matrix 
are used to immobilize and store FGF-2 and other heparin binding 
proteins [8-11] including HIV-Tat [12,13]. Tat may also exit HIV-
infected cells via non-conventional pathways, and binds to HSPG with 
an affinity similar to FGF-2 [13]. Many biological activities of Tat in 
cultured cells, such as induction of endothelial cell growth, migration, 
and invasion, are enhanced by low concentrations and inhibited by 
high concentrations of heparin, as has been shown for FGF-2 [12,13]. 
However, the mechanisms by which FGF-2 or HIV-Tat are released 
and/or activated in KS lesions is not fully understood. In previous 
studies we have found that a Fibroblast Growth Factor Binding Protein 
(FGFBP1 or BP1), which was first identified in a tumor cell line [14], 
is a carrier molecule for FGF-2. Subsequent studies demonstrated that 
BP1 binding releases FGF-2 from the HSPG and can transport bound 
FGF-2 to the target cell surface [15,16]. Taken together, these findings 
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suggest that FGF-2, BP1, and HIV-Tat may have significant overlapping 
biological interactions in the pathogenesis of KS. Thus, we carried out 
this study to determine whether BP1 is expressed in KS lesions, and 
to define whether BP1, FGF-2, and HIV-Tat have significant protein-
protein interactions that could play a potential clinically role in the 
pathogenesis of AIDS-KS. 
Methods
Patients
This study was approved by the Institutional Review Board from 
the Children's National Medical Center. The diagnosis of HIV-1 
infection and KS were done by the attending physicians following 
standard clinical and pathologic criteria. KS tissues were obtained from 
biopsies or autopsies of patients with AIDS-KS lesions in the skin (n 
=2), lung (n=1), gastrointestinal tract (n=1), and from one KS tumor 
harvested from the skin of an HIV-negative patients. Control sections 
were obtained from AIDS patients without KS: skin (n =2); liver (n=1), 
lung (n=1), gastrointestinal tract (n=1). 
Immunohistochemisty
 Tissues were fixed in 10% neutral buffered formalin and embedded 
in paraffin. Paraffin sections were cut at 4 μm, deparaffinized and 
rehydrated. Sections were then heated twice for 5 min each in 0.01 
M sodium citrate (pH 6.0) in a microwave oven (2450 mHz, 850 w) 
to augment antigen retrieval. Endogenous peroxidase activity was 
blocked by treating with 3% H2O2 in 100% methanol for 10 min. 
Immunostaining was performed with a commercial streptavidin-
biotin-peroxidase complex HistostainTM SP kit (Zymed, South San 
Francisco, CA, USA) according to the manufacture‘s instructions as 
previously described [17]. We used a rabbit polyclonal BP1 antibody 
diluted 1:50 in 2% BSA PBS [17]. The specificity of this BP1 antibody 
has been demonstrated before [17,18]. To determine the localization 
of FGF-2 we used a monoclonal antibody against bovine FGF-2 
from Upstate Biotechnology (Lake Placid, NY, USA). Different cell 
types in the KS lesions were identified with antibodies against von 
Willebrand factor (vWF) and CD68, for mononuclear cells, all from 
Dako (Carpinteria, CA, USA). The co-localization of BP1 in infiltrating 
mononuclear cells was performed by using Histostain-DSTM double 
staining kit (Zymed). Controls sections included replacing the primary 
antibody with equivalent concentrations of mouse non immune IgG, 
or a control polyclonal rabbit immunoglobin preparation derived from 
non-immune rabbit, and omitting the first antibodies. 
In situ hybridization
In situ hybridization studies for FGF-BP were done in 4 μm sections 
as previously described [17]. Briefly, these sections were heat-fixed for 30 
min. at 65°C and deparaffinized. After a 30-min. incubation in 5 mmol/L 
levamisole, they were washed in PBS and in DEPC-treated water for 5 
min., immersed in 0.2 mol/L HCl for 20 min, and digested with 20-40 
μg/ml proteinase K (Sigma) for 10 min. at 37°C. Slides were hybridized 
with a 790-bp human FGF-BP RNA probe (Gene Bank # M60047). This 
fragment was subcloned into the Hind III and XbaI sites of the pRC/
CMV vector between T7 and SP6 promoters as previously described 
[17]. For both probes, in vitro transcription reactions were performed 
with SP6 or T7 RNA polymerase in the presence of DIG-UTP by using 
a DIG RNA labeling Kit (Boehringer-Mannheim Biochemica). Labeling 
efficiency of the riboprobe was estimated by comparison with 10-fold 
serial dilution of a digoxigenin-labeled control riboprobe and direct 
detection of the labeled riboprobe with antidigoxigenin antibodies. 
Riboprobe concentrations were adjusted to be equivalent on the basis 
of the labeling efficiency before use in the in situ hybridization studies. 
The BP1 probe was used at a final concentration of 0.1-0.5 ng/μl in 
hybridization buffer. Subsequently the slides were washed and incubated 
with anti-digoxigenin antibody conjugated with alkaline phosphatase 
(Boehringer- Mannheim Biochemica) at the dilution of 1:750 for 30 
min. at 37°C. The negative controls included: (1) hybridization with the 
sense probe, (2) RNase A (100 μg/ml in 10 mM Tris HCl, pH 8.0,1 mM 
EDTA) pretreatment before hybridization, and (3) omission of either the 
antisense RNA probe or the anti-digoxigenin antibody.
Binding studies
Briefly, 96 wells plates (EIA/RIA Strip Plate, Corning Inc. Corning 
NY) were coated with Histidine-tagged BP1 (0.1 ng/ml) diluted in Tris 
Buffered Saline. Excess of unbound His-BP was removed by washing. 
Non-specific binding was blocked by adding 300 μl (LB media) and 
further washes. [125]I-FGF-2 (1-20 μg/ml) was added to the wells at 
RT0 with constant rocking for two hours, and then, unbound FGF-2 
was removed by washing. The binding of radiolabeled FGF-2 to His-BP1 
was measured by counting radioactive emission from the individual 
wells. In some experiments we added HIV-Tat (1-3000 ng/ml) together 
with (1-20 μg/ml) FGF-2, to determine whether Tat can compete with 
FGF-2 for its binding to BP-FGF, or 1 hr later after addition of [125]
I-FGF-2, to determine whether Tat can dissociate the complex FGF-
2/BP1. To determine the specificity of Tat activity other experiments 
were done in the presence or absence of Nef and gp120 (1-3000 ng/ml). 
The HIV-1 recombinant peptides were provided by National Institute 
of Allergy and Infectious, Diseases, NIH AIDS Research and Reference 
Reagent Program: Tat (contributor Dr. John Brady); SIVnef (contributor 
Dr. Jose Torres); HIV-1IIIB gp120 (contributor NIAID, produced 
by ImmunoDiagnostics, Inc). [125]-I-FGF2 was purchased from 
Amersham Pharmacia Biotech (Piscataway, NJ). Human recombinant 
FGF-2 was purchased from Life Technologies, Inc (Gaithersburg, MD). 
Recombinant histidine-tagged BP1 protein purification was produced 
in Sf-9 insect cells with a baculovirus vector that contains an expression 
cassette for human BP1 (BAC-To-BAC Baculovirus Expression System, 
Life Technologies Inc., Gaithersburg, MD) as previously described (15-
16). In addition, binding studies of [125]I-FGF-2 to its high and low 
affinity receptors were done in the presence or absence of BP1.These 
studies utilized recombinant FGFR-1/Fc chimera (from R &D Systems 
Inc., Catalog # 658-FR, Minneapolis, MN), containing the extracellular 
domain of human FGFR-1 fused via a polypeptide linker to the carboxy-
terminal Fc region of human IgG1. The binding interactions between 
BP1 and HIV-Tat were evaluated by using saturation binding curves 
and by competitive displacement of the [125I] FGF–2 ligand with an 
excess of cold ligand (Tat or BP1).
BP1 transgenic mice
The generation of the tetracycline-regulated conditional BP1 
transgenic mice, and the impact of BP1 on angiogenesis and wound 
healing, were previously described by Tassi et al. [19]. BP1 transgene 
(Tg) expression is silenced by feeding these mice a diet supplemented 
with an orally available tetracycline (e.g. doxycycline) from Bio-Serv 
(Frenchtown NH) (BP1 OFF) and induced by a switch to regular mouse 
chow that lacks tetracycline (BP1 ON), typically for 2 weeks before the 
experiments. The dorsal skin of BP1 OFF and BP1 ON animals was 
injured by a full-thickness dermal biopsy punch (3 mm diameter) 
under anesthesia, as previously described [19]. Histological sections 
were then screened for the presence / absence of KS-like lesions. 
Immunohistochemistry studies were done to detect the infiltration 
of macrophages using the F4/80 antibody (Serotec, Raleigh, NC) as 
described by Tassi et al. [19]. Animals experiments were reviewed and 
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approved by the Institutional Animal Care and Use Committee at both 
institutions, Children’s National Medical Center, and Lombardi Cancer 
Center, at Georgetown University, Washington DC. 
Statistical analyses
Results are expressed as the mean value + SD. Difference between 
two groups were compared by Students’t test. P-values less than 
0.05 were considered significant. When more than two means were 
compared, difference was measured by one way analysis of variance 
followed by multiple comparisons using the Student-Neuman-Keul's 
test.
Results 
BP1 expression in AIDS Kaposi’s sarcoma (KS)
Since FGF-2 was detected in samples of both classic KS and AIDS-
KS [5,6] (Figure 1E) and is considered to play an important role in the 
pathogenesis of AIDS-KS [5], we explored whether BP1 is expressed 
in AIDS-KS tumors. BP1 expression was detected in keratinocyes, 
spindle cells and in mononuclear cells infiltrating KS tumors. The BP1 
protein was visualized by immunohistochemistry (Figure 1) and the 
mRNA by in situ hybridization (Figure 2). The expression of BP1 was 
not limited to KS lesions in the skin but was also detected in KS lesions 
in the intestine (data not shown). BP1 expression was higher in focal 
KS tumor areas and infiltrating cells, when compared to normal skin 
and keratinocytes where BP1 expression is detectable in the absence of 
tumors [15,20] (data not shown). The expression of BP1 in KS spindle 
cells, as well as infiltrating mononuclear cells located in close proximity 
to tumor vessels, strongly suggests that local production and release 
of BP1 functions to enhance the angiogenic activity of FGF-2 in these 
structures.
HIV-Tat competes with FGF-2 for binding to BP1
HIV-Tat protein, although initially described as a nuclear 
transcriptional regulatory protein, has also been shown to function as 
an angiogenic heparin-binding growth factor [12,13]. Moreover, Tat 
Figure 1: Detection of BP1 and FGF-2 in Kaposi’s sarcoma skin lesions by immunohistochemistry. Panels A and B show localization of BP1 protein (red color) 
in AIDS-KS skin lesions pointed by the black arrows (A, 200X; B, 500X). Panel C shows capillary endothelial cells stained positive with vWF (dark color) located in 
close proximity to infiltrating cells expressing BP1 (red color) and pointed by the black arrows (500X). Panel D shows co-localization of BP1 (red color) in infiltrating 
mononuclear cells stained also with an antibody against the CD-68 antigen (dark color) in a KS skin lesions (500X). Dual BP1 and CD68 positive cells are pointed by the 
black arrows. Panel E, shows the localization of FGF-2 (red color) in an AIDS-KS skin lesion. FGF-2 was localized in endothelial cells, infiltrating spindle cells, and the 
extracellular matrix (500X). Panel F shows vWF positive endothelial cells in an AIDS-KS skin tumor (dark color), and infiltrating BP1 positive cells (red color) surrounding 
the vessels. Black arrows point to the BP1 positive cells (500X). 
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Figure 2: Detection of BP1 mRNA in a Kaposi’s sarcoma skin lesions by in situ 
hybridization. Panels A and C show localization of BP1 mRNA (dark violet color) in representative KS sections hybridized with the antisense BP1 probe. Panels B and 
D show similar KS sections hybridized with the sense BP1 probe (Original magnification 500X). 
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Figure 3: Effect of HIV-Tat protein on FGF-2 binding to BP1 (A) or FGF receptor (B) in cell-free binding assays with recombinant proteins. 
A. Immobilized recombinant human BP1 protein was incubated with [125]-I-FGF-2 in the absence (control) or presence of different competitors: FGF-2, HIV-Tat, Nef 
and gp120. Data points represent specific binding of [125]-I-FGF-2 after subtraction of binding to wells coated with blocking solution only. Competition for [125]-I-FGF-2 
binding was only observed with cold FGF-2 or HIV Tat protein as competitors. *, p<0.05 relative to "FGFBP only". 
B. An FGF receptor-IgG fusion protein (500 ng/ml; FGFR1) and [125]-I-FGF-2 (20 ng/ml) were incubated with protein A/G agarose beads, in the absence (control) 
or presence of cold FGF-2, Tat, Nef, or gp120. One sample set with the receptor protein and radiolabeled FGF-2 was also run without the FGFR-IgG fusion protein 
(“No FGFR1”). Washed beads were collected and bound radioactivity was detected and is expressed relative to control. Bars are means of triplicates + SEM from one 
representative experiment. This experiment was repeated twice. There was no significant difference in receptor binding of [125]-I-FGF-2 in control samples versus 
those containing Tat, Nef, or gp 120. In the absence of FGF receptor protein or with added cold FGF-2 significantly less ligand binding was observed. *, p<0.05 relative 
to "FGFR1 only"; #, no significant difference between "+Cold FGF-2" and "No FGFR1". 
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and FGF-2 synergize to induce an aggressive and highly angiogenic 
phenotype of AIDS-Kaposi’s sarcoma [5]. Therefore, we investigated 
its potential role in affecting the interactions between FGF-2 and BP1 
in vitro. Two other HIV-proteins, Nef and gp120 were also tested to 
determine the specificity of the Tat effects in this process. As shown in 
Figure 3A, the HIV-Tat protein inhibited the binding of radiolabeled 
FGF-2 to the immobilized BP1 protein to the same extent as unlabeled 
(“cold”) FGF-2. In contrast, HIV-Nef and HIV-gp120 used at the same 
concentrations as HIV-Tat, had no effect on [125]I-FGF2 binding 
to immobilized BP1.  DDT-treated BSA. BSA was used as a further 
negative control and showed no interference with the FGF-2 / BP1 
interaction. We conclude from these findings that Tat binding to FGF-
2 overlaps with FGF2 / BP1 interaction site(s) or generates a steric 
hinderance for FGF-2 binding. 
HIV-Tat protein does not interfere with FGF-2 binding to 
FGFR1
Since HIV-Tat protein acts as an angiogenic growth factor and 
can bind FGF-2, we carried out additional in vitro experiments 
to determine whether HIV-Tat may interfere with the binding of 
FGF-2 to FGFR1. In these experiments, [125]I-FGF2 was added to 
immobilized, recombinant FGFR1 protein in the absence or presence 
of Tat (>1,000-fold excess relative to the [125]I-FGF2 concentration). 
As shown in Figure 3B even an excess concentration of HIV-1 Tat 
protein does not inhibit FGF-2 binding to the FGFR1. In contrast, an 
excess concentration of cold FGF-2 blocked the binding of FGF-2 to the 
immobilized FGFR1 to background levels (Figure 3B, “No FGFR1”). 
Similar to Tat, the HIV-proteins Nef and gp120 also failed to inhibit 
FGF-2/FGFR1 interactions. From these data we conclude that Tat does 
not inhibit the interactions of FGF-2 with its high affinity receptor in a 
cell-free assay.
Conditional BP1 transgene expression induces KS-like skin 
lesions during wound healing
A previous study by Tassi et al. showed that BP1 induced angiogenic 
lesions in the skin of BP1 ON conditional transgenic mice by 3-fold 
during wound healing [19]. This effect of BP1 on angiogenesis was 
strictly dependent on FGF signaling because systemic treatment of 
animals with an FGFR inhibitor (PD173074) prevented the induction 
of angiogenesis [19]. When we re-examined the histological samples 
from this study series, we found that many of the skin lesions show 
proliferating spindle cells, dilated capillaries, interstitial edema, and 
infiltrating inflammatory cells that resemble KS lesions (Figure 4).
Discussion 
In this study, we have described a potential novel mechanism by 
which the release and activity of FGF-2 can be modulated in AIDS-
KS lesions. More specifically, we have found that a secreted FGF-
binding protein (FGFBP1 or BP1) is produced by KS spindle cells, 
and by mononuclear cells infiltrating these vascular tumors. Since BP1 
facilitates the release of FGF-2 from the extracellular matrix [15,16,20], 
and can modulate the binding interactions of FGF-2 with HSPG, these 
findings suggest that BP1 could potentially regulate the release and the 
paracrine activity of FGF-2 in KS lesions [21]. 
In general, the biological activity of FGF-2 is quenched by its tight 
binding to HSPG located in the extracellular matrix [22,23]. Thus, to 
become active, FGF-2 needs to be released and solubilized to reach its 
target cells in a paracrine activity mode [9]. One established mechanism 
that can solubilize FGF-2 from this storage site is the digestion of 
the glycosaminoglycan portion of the cell attachment molecule by 
heparanases [24-27]. Indeed, peripheral blood mononuclear cells 
(PBMC’s) can release heparanase activities that can in turn release 
active FGF-2 from the local storage in the extracellular matrix [25,28]. 
Figure 4: KS-like skin lesion in BP1 expressing transgenic mice. The upper panels show representative hematoxylin and eosin (H&E) stained sections of excisional 
skin wounds from transgenic mice with the BP1 transgene OFF or ON four days after wound healing. The lower panels show representative macrophage (F4/80) stained 
sections of excisional skin wounds from transgenic mice with BP1 OFF or ON four days after the initial skin injury. Original magnification 250X.
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Furthermore, proteases that can digest the protein backbone of the 
HSPG could also release FGFs from the immobilized state and thus 
contribute to their activation [26,27]. For example, normal endothelial 
cells do not release FGF-2, do not proliferate in response to exogenous 
Tat, and do not induce the development of KS like lesions when injected 
into nude mice [28-30]. However, when normal endothelial cells are 
exposed to conditioned media from activated T cells, they acquire a 
spindle cell morphology, produce and release FGF-2 [29-31] and become 
responsive to HIV-Tat. Thus it is possible that proteolytic enzymes (i.e, 
plasmin, thrombin) [12,13] or chemokines (i.e., interferon γ) [29-31] 
produced by activated T cells could facilitate the release of FGF-2 from 
normal endothelial cells or other target cells. However, the extent of the 
role of heparanases, cytokines, and/or proteases for the release of FGF-2 
in the context of KS, is not clearly defined at the present time. 
Our data suggest an alternative mode of delivering active FGF-2 
from the ECM storage site to its receptor could be via non-covalent 
binding to a secreted carrier protein. Such a secreted binding protein for 
FGFs was described by Sato and co-workers in 1991 [14]. This protein 
was purified from supernatants of A431 cells by virtue of its ability to 
bind with high affinity to FGF-2 using ligand affinity chromatography 
with immobilized FGF-2 as the crucial step [14]. BP1 contains a 
hydrophobic signal sequence and binds to FGF-1 and FGF-2 in a non-
covalent, reversible manner [14], and releases immobilized FGF-2 from 
storage in the extracellular matrix of cultured cells that express both 
BP1 and FGF-2. This mobilized FGF-2 is biologically active [15,16]. 
Sato and coworkers also demonstrated that pre-incubation of FGF-2 
with purified BP1 protein protects the mitogenic activity of FGF-2 from 
inactivation [14]. These characteristics make BP1 an excellent candidate 
carrier molecule for FGF-2. BP1 can also support tumor growth and 
angiogenesis of FGF-2 expressing non-tumorigenic SW-13 cells [15]. 
Expression of this binding protein in cell lines which express FGF-2 
leads to a tumorigenic and angiogenic phenotype [15,16]. Moreover, 
BP1 transfected cells release the protein into their media together with 
FGF-2 in a non-covalently bound form. This released FGF-2 becomes 
activated biologically, and the growth phenotype of cells expressing BP1 
can be blocked by a specific antibody for FGF2 [15,16]. Taken together, 
these studies support the notion that the secretion of BP1 may be an 
important activating step for the locally stored FGF-2 in KS lesions.
Previous studies have shown that HIV-Tat synergizes with FGF-2 
to induce the proliferation of endothelial and KS spindle cells. More 
recently we found that the heparin binding motif of HIV-Tat plays a 
crucial role facilitating its recruitment to lipid rafts and induction of 
FGF-2 signaling [32]. Here, we report that HIV-Tat competes with 
FGF-2 for binding to BP1, but does not disrupt the binding of FGF-2 to 
it’s high affinity receptor FGFR1 (Figure 3). Thus, an equilibrium must 
exists in the extracellular matrix of KS tumors, keeping FGF-2 bound 
to immobilized HSGPs. In this manner, HSPGs act as a depot that keep 
free FGF-2 at a sufficiently low concentration, preventing target cell 
receptor activation. Our findings show that BP1 can be produced by 
multiple KS cells, including infiltrating mononuclear cells located in 
close proximity to the tumor vessels. Thus, since BP1 is a soluble carrier 
protein that can bind FGF-2 molecules available in solution, it might 
also release FGF-2 molecules from HSPGs located on the cell surface 
of tumor vascular endothelial cells. Moreover, BP1 reduces the binding 
affinity of FGF-2 for HSPGs [14-16] and by this BP1 can amplify the 
angiogenic activity of FGF-2 in the KS tumor environment. Finally, 
it is worth noting that our results clearly show that the expression 
of BP1 is not limited to AIDS-KS lesions. BP1 was also detected in 
similar locations in the skin of HIV-negative KS tumors, as well as in 
injured tissues from HIV-infected patients without KS (e.g. kidney). 
Furthermore, in a previous study we showed that BP1 staining was 
significantly up-regulated in pre-malignant human skin lesions and 
during wound healing when compared to normal skin [33]. Moreover, 
both FGF-2 and BP1 are produced by infiltrating mononuclear cells 
[7], which are not detected in normal skin, providing an additional 
source of BP1 and FGF-2 release during inflammation. Thus, BP1 may 
play a more general role modulating the angiogenic activity of FGF-2 
in different tissues of HIV-infected patients undergoing inflammatory 
lesions, including the kidney [17]. 
The protein coding sequence of the 234 amino acid FGFBP1 is 
contained in a single exon and the gene is located on chromosome 4 
in human and the respective syntenic loci in other vertebrates [34]. 
We identified the C-terminal 44 amino acids in FGFBP1 as the FGF 
binding domain [35]. Other portions of the protein interact with 
heparin. Interestingly, cysteins positions in the protein are conserved 
across species and can form disulfide bridges that will stabilize the 
protein when bound to an FGF [35]. Amino acid sequence and protein 
structure comparisons of secreted FGFBP1 with the well-defined FGF 
binding domain in the transmembrane FGF receptors did not reveal 
any common features of the domains [9,35]. This suggests that the 
respective FGF binding domains in FGFBP1 and in FGF receptors 
evolved independently and will bind to distinct surfaces on FGFs. 
Furthermore, in the presence of FGFBP1 an enhanced receptor 
signaling activity of FGFs was observed supporting the notion that 
binding of FGFs to their receptor and to FGFBP1 do not overlap or 
generate a steric hindrance of ligand access to the receptor [9,15,19]. 
In summary, we have shown that a FGF binding protein (FGFBP1) 
which is known to positively modulate the angiogenic and growth 
promoting activity of FGF’s in tumor cells [15,16], is expressed in 
keratinocytes, infiltrating mononuclear cells, and KS spindle cells. 
In addition, we found that the HIV-Tat can modulate the binding 
interactions of BP1 and FGF-2. Finally, we found that activation 
of BP1 during the process of wound healing in the skin, can induce 
angiogenic lesions that resemble KS. Taken together, when these 
findings are interpreted in the context of previous studies, they provide 
a novel mechanism by which the activity of FGF-2 and HIV-Tat can be 
modulated in AIDS-KS tumors.
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